Insulin glargine

Drugs

Volumn 59, Issue 2, 2000, Pages 253-260

  Gillies, Peter S ^a   Figgitt, David P ^a   Lamb, Harriet M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLARGINE; GLUCOSE; HUMAN INSULIN; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; RECOMBINANT HUMAN INSULIN; SULFONYLUREA; UNCLASSIFIED DRUG; ZINC;

CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SUSTAINED RELEASE PREPARATION;

EID: 0034068278     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059020-00009     Document Type: Review

References (24)

1. 1. Mandrup-Poulsen T. Diabetes. BMJ 1998 Apr 18; 316: 1221-5
2. 2. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999 Mar; 22 Suppl. 2: 109-13
3. 3. Home P. Insulin glargine: the first clinically useful extended-acting insulin in half a century? Expert Opin Invest Drug 1999 Mar; 8: 307-14
4. 4. Berti L, Seffer E, Seipke G, et al. Human insulin analog HOE901: characteristics of receptor binding and tyrosine kinase activation [abstract]. Diabetes 1995 May; 44 Suppl. 1: 243
5. 5. Bähr M, Kolter T, Seipke G, et al. Growth promoting and metabolic activity of the human insulin analogue [Gly(A21), Arg(B31),Arg(B32)]insulin (HOE 901) in muscle cells. Eur J Pharmacol 1997 Feb 12; 320: 259-65
6. 6. Seipke G, Berchthold H, Geisen K, et al. HOE901 - a new insulin with prolonged action [abstract]. Eur J Endocrinol 1995 Apr; 132 Suppl. 1: 25
7. 7. Linkeschowa R, Heise T, Rave K, et al. Time-action profile of the long-acting insulin analogue HOE901 [abstract]. Diabetes 1999 May; 48 Suppl. 1:97
8. 8. Soon PC, Matthews DR, Rosskamp R, et al. 24h profile of action of biosynthetic long-acting insulin (HOE901) tested in normal volunteers by glucose clamp methodology [abstract]. Diabetes 1997 May; 46 Suppl. 1: 161
9. 9. Dreyer M, Pein M, Schmidt C, et al. Comparison of the pharmacokinetics/dynamics of Gly(A21)-Arg(B31,B32)-human-insulin (HOE71GT) with NPH-insulin following subcutaneous injection by using euglycaemic clamp technique [abstract]. 15th International Diabetes Federation Congress; 1994 Nov 6-11; Kobe, Japan, 252
10. 10. Scholtz HE, van Niekerk N, Meyer BH, et al. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 comopared to NPH and ultralente human insulins using the euglycaemic clamp technique [Abstract no. 882]. Diabetologia 1999; 42 Suppl. 1: A235
11. 11. Lepore M, Kurzhals R, Pampanelli S, et al. Pharmacokinetics and dynamics of s.c. injection of the long-acting insulin glargine (HOE1) of TIDM [abstract]. Diabetes 1999 May; 48 Suppl. 1: 97
12. 12. Coates PA, Mukherjee S, Luzio S, et al. Pharmacokinetics of a long-acting human insulin analogue (HOE901) in healthy subjects [abstract]. Diabetes 1995 May; 44 Suppl. 1: 130A
13. 13. Luzio SD, Owens D, Evans M, et al. Comparison of the sc absorption of HOE 901 and NPH human insulin type 2 diabetic subjects [abstract]. Diabetes 1999 May; 48 Suppl. 1: 111
14. 14. Ratner RE, Hirsch IB, Mecca TE, et al. Efficacy and safety of insulin glargine in subjects with type 1 diabetes: a 28 week randomized, NPH insulin-controlled trial [abstract]. Diabetes 1999 May; 48 Suppl. 1: 120
15. 15. Rosenstock J, Park G, Zimmerman J. Efficacy and safety of HOE 901 in patients with type 1 DM: a four-week randomized, NPH insulin-controlled trial [abstract]. Diabetes 1998 May; 47 Suppl. 1: 92
16. 16. Pieber TR, Eugène-Jolchine I, Derobert E. Efficacy and safety of HOE901 in patients with type 1 diabetes: a four-week randomised, NPH insulin-controlled trial [abstract]. Diabetologia 1998 Aug; 41 Suppl. 1: 49
17. 17. Raskin P, Park G, Zimmerman J. The effect of HOE 901 on glycemic control in type 2 diabetes [abstract]. Diabetes 1998 May; 47 Suppl. 1: 103
18. 18. Rosenstock J, Schwartz S, Clark C, et al. Efficacy and safety of HOE 90I (insulin glargine) in subjects with type 2 DM: a 28-week randomized, NPH insulin-controlled trial [abstract]. Diabetes 1999 May; 48 Suppl. 1: 100
19. 19. Matthews DR, Pfeiffer C, Multicentre HOE901 Research Group. Comparative clinical trial of a new long-acting insulin (HOE901) vs protamine insulin demonstrates less nocturnal hypoglycaemia [abstract]. Diabetes 1998 May; 47 Suppl. 1: 101
20. 20. Schoenle E. Insulin glargine (HOE 901) lowers fasting blood glucose in children with type 1 diabetes mellilus without increasing the risk of hypoglycaemia [abstract no. 883]. Diabetologia 1999; 42 Suppl. 1: A235
21. 21. Garg S, Gerard L, Pennington M, et al. Efficacy of the new long acting insulin analog (HOE901) on fasting glucose values in IDDM [abstract]. Diabetes 1998 May; 47 Suppl. 1: 359
22. 22. Talauticar M, Willms B, Rosskamp R. Efficacy of HOE901 following subcutaneous injection for four days in type 1 diabetic subjects [abstract]. 15th International Diabetes Federation Congress; 1994 Nov 6-11; Kobe, Japan, 247
23. 23. Pieber TR, Eugène-Jolchine I, Derobert E, et al. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000; 23 (2): 157-62
24. 24. Bradley C, Witthaus E, Stewart J. Treatment satisfaction and psychological well-being in patients with type 1 diabetes, treated with a new long-acting insulin, insulin glarginc [abstract]. Diabetes 1999 May; 48 Suppl. 1: 353